GILEAD SCIENCES, INC.

GILD · CIK 0000882095

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$29.44B2.4%

FY2025

Net income (FY)

$8.51B1,672.9%

FY2025

Free cash flow (FY)

$9.46B8.2%

FY2025

Diluted EPS (FY)

$6.781,684.2%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 7.0× since FY2007 · net margin 37.5% → 28.9%

MarginsNet marginFCF margin

FY2025: net 28.9% · free cash flow 32.1% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $10.02B operating cash − $563.0M capex = $9.46B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 46% (FY2008) → 37% (FY2025) · on assets 14.4%

The receipts

GILEAD SCIENCES, INC.

GILD · CIK 0000882095

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$29.44B2.4%

FY2025

Net income (FY)

$8.51B1,672.9%

FY2025

Free cash flow (FY)

$9.46B8.2%

FY2025

Diluted EPS (FY)

$6.781,684.2%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 7.0× since FY2007 · net margin 37.5% → 28.9%

MarginsNet marginFCF margin

FY2025: net 28.9% · free cash flow 32.1% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $10.02B operating cash − $563.0M capex = $9.46B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 46% (FY2008) → 37% (FY2025) · on assets 14.4%

The receipts